were among the worst-performing health-related stocks Tuesday, sliding 15% after the medical-device maker's first-quarter results missed analyst forecasts.
The company earned $8.8 million, or 32 cents a share, on revenue of $23.7 million. Excluding items, the company earned $10.3 million, or 37 cents a share. Analysts polled by Thomson First Call expected earnings of 42 cents a share and revenue of $24 million. During the year-earlier quarter, the company earned $7.5 million, or 27 cents a share, on revenue of $18.5 million. Excluding items, year-earlier earnings were $8.6 million, or 32 cents a share. Shares were down $3.85 to $22.64.
jumped 10% after the biopharmaceutical company posted better-than-expected first-quarter results. The company reported a loss of $12.7 million, or 30 cents a share, on revenue of $12.1 million. Analysts expected a bigger loss of 42 cents a share and revenue of $9.1 million. A year earlier, the company recorded a loss of $25 million, or 79 cents a share, on revenue of $4.4 million. Shares were up $1.37 to $14.59.
National Medical Health Card Systems
( NMHC) tumbled 25% after the pharmacy-benefit manager posted disappointing third-quarter results. The company reported earnings of $130,000, or 2 cents a share, including one-time charges of $1.3 million. Analysts expected earnings of 29 cents a share. Revenue totaled $215.7 million, short of analysts' projection of $223.7 million. During the year-earlier period, National Medical earned $1.8 million, or 27 cents a share, on revenue of $199.3 million. "We have had a disappointing sales year which has translated into weak third-quarter earnings," the company said. "Our sales forecasts anticipated the conversion of a number of accounts that have not occurred or have had significant delays."
The company now sees fiscal 2006 earnings of $9.5 million to $10 million, well below its earlier view of about $16 million. Shares were trading down $5.91 to $16.91.
Albany Molecular Research
rose 5% after the drug discovery company posted first-quarter results that topped forecasts. The company earned $1.9 million, or 6 cents a share, on contract revenue of $36.2 million. Including recurring royalties, the company's total revenue was $43.4 million. Analysts expected earnings of 2 cents a share and revenue of $35.8 million. Last year, the company recorded a first-quarter profit of $5.6 million, or 17 cents a share, on revenue of $36.6 million. Including royalties, the company reported total revenue of $48.6 million a year ago.
Looking ahead, Albany Molecular sees second-quarter contract revenue of $36 million to $39 million. For all of 2006, the company continues to predict contract revenue of $150 million to $160 million. Shares were up 54 cents to $10.39.
rose 8% after the hospital products company posted higher-than-anticipated first-quarter results. The company earned $80.2 million, or 49 cents a share, on revenue of $664.3 million. Excluding items, Hospira earned $101.9 million, or 62 cents a share. Analysts expected earnings of 48 cents a share and revenue of $650.8 million. During the year-earlier period, the company earned $77.2 million, or 49 cents a share, on revenue of $662.1 million. Excluding items, the company earned $87.2 million, or 55 cents a share, a year earlier.
For 2006, Hospira expects adjusted earnings of $1.97 to $2.02 a share. Analysts project earnings of $1.97 a share. Shares were trading up $2.95 to $41.67.
Other health care volume movers included
, down $1.38 to $43.70;
, down 50 cents to $21.43;
, down 1 cent to $25.53;
, up 12 cents to $48.17;
Bausch & Lomb
( BOL), down 82 cents to $43.86;
, down 42 cents to $67.63;
, down 66 cents to $38.01;
, down $1.24 to $70.36;
Johnson & Johnson
, down 26 cents to $58.45; and
( SGP), down 7 cents to $19.28.